Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned. The aim of this study is to define the incidence and clinical consequences of PALN

Trial Details

NCT ID
NCT06065891
Phase
NA
Sponsor
Jon Unosson
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • PALN resection
Locations (sample)
  • Odense, Denmark|55.39594,10.38831
  • Gothenburg, Sweden|57.70716,11.96679
  • Linköping, Sweden|58.41086,15.62157
  • Lund, Sweden|55.70584,13.19321
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Resectable suspected periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)
  • Borderline resectable periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020)
  • Age \>18 years
  • Written patient consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →